Search

Your search keyword '"Koutsogiannouli, E. A."' showing total 5 results
Start Over Author "Koutsogiannouli, E. A."
5 results on '"Koutsogiannouli, E. A."'

1. Regulation of expression of the p21CIP1 gene by the transcription factor ZNF217 and MDM2

Author

Mantsou, A. Koutsogiannouli, E. Haitoglou, C. Papavassiliou, A.G. Papanikolaou, N.A.

Subjects
enzymes and coenzymes (carbohydrates)
Abstract

Using mouse double minute 2 (MDM2) protein-specific affinity chromatography and mass spectrometry, we have isolated the protein product of the oncogene znf217, which is a transcription factor and a component of a Hela-S-derived HDAC1 complex, as a novel MDM2-interacting protein. When co-expressed in cultured cancer cells, ZNF217 forms a complex with MDM2 and its ectopic over-expression reduces the steady-state levels of acetylated p53 in cell lines, suppressing its ability to activate the expression of a p21 promoter construct. In-silico analysis of the p21 promoter revealed the presence of several ZNF217-binding sites. These findings suggest that MDM2 controls p21 expression by at least 2 mechanisms: through ZNF217-mediated recruitment of HDAC1/MDM2 activity, which inhibits p53 acetylation; and through direct interaction with its binding site(s) on the p21 promoter. © 2016 Published by NRC Research Press.

Published
2016

5. [Epigenetics in urothelial cancer: Pathogenesis, improving diagnostics and developing novel treatment options].

Author

Niegisch G, Hoffmann MJ, Koutsogiannouli EA, and Schulz WA

Subjects
Animals, Humans, Models, Genetic, Molecular Diagnostic Techniques methods, Urinary Bladder Neoplasms therapy, Epigenesis, Genetic genetics, Genetic Predisposition to Disease genetics, Genetic Testing methods, Genetic Therapy methods, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms genetics
Abstract

Urothelial carcinoma of the bladder is a common tumor for which improvements in diagnostic markers and new therapy approaches, in addition to or combined with standard chemotherapy, are urgently required. Epigenetic alterations could provide both novel diagnostic markers and therapeutic targets as they are emerging as crucial factors in the development and progression of this tumor type, likely contributing to altered differentiation and metastatic potential. These alterations affect DNA methylation, histone modifications, chromatin remodeling, long noncoding RNAs, and microRNAs. Factors involved in histone modifications and chromatin remodeling appear to be particularly frequently inactivated by mutations. Thus, histone-modifying enzymes may represent good targets for rational new therapeutic approaches, although thorough investigation of their complex functions is a prerequisite. DNA methylation changes and altered miRNA expression provide promising biomarkers for diagnosis and prognosis that need further validation in comprehensive and well-standardized studies.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results